Exploring the mechanism of chronic insomnia
Promotional material from Idorsia Pharmaceuticals UK Ltd.
References
1 – QUVIVIQ™▼ (daridorexant) Idorsia Pharmaceuticals Ltd, Summary of Product Characteristics.
2 – Roch C, et al. Psychopharmacology. 2021; 238(10): 2693–2708.
3 – NICE Clinical Knowledge Summary (CKS) Insomnia: Scenario: Managing long-term insomnia (more than 3 months duration). Available at: https://cks.nice.org.uk/topics/insomnia/management/managing-insomnia/. Updated May 2025. Accessed June 2025.
4 – Mignot E, et al. Lancet Neurol. 2022; 21(2): 125–139.
5 – American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision. Arlington, VA, American Psychiatric Association Publishing, 2022.
6 – Scammell TE and Winrow CJ. Annu Rev Pharmacol Toxicol. 2011; 51: 243–266.
7 – Riemann D, et al. Sleep Med Rev. 2010; 14(1): 19–31.
8 – Nofzinger E, et al. Am J Psychiatry. 2004; 161: 2126–2129.
9 – Saper C, et al. Nature. 2005; 437(7063): 1257–1263.
This information is intended for UK healthcare professionals.
Adverse events must be reported. Healthcare professionals are asked to report any suspected adverse reactions via http://www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google play or Apple App store. Adverse events should also be reported to ds.safety.uk@idorsia.com.
